Recent Advances in Nanozymes for the Treatment of Atherosclerosis

作者：Zheng Zou, Xiaojun Bi, Huan Ma, Ligang Chen, Hai Bo Jin, Shun Gong, Xinning Li, Xiyu Liu · 发表于：International Journal of Nanomedicine · 年份：2025 · DOI：10.2147/ijn.s540010 · 被引用次数：13 · 研究领域：Advanced Nanomaterials in Catalysis、Nanoplatforms for cancer theranostics、Nanocluster Synthesis and Applications

Atherosclerosis (AS) is a complex, multifactorial cardiovascular disease characterized by lipid accumulation, chronic inflammation, oxidative stress, and endothelial dysfunction. Conventional therapies, including lipid-lowering and anti-inflammatory agents, offer limited efficacy due to inadequate lesion targeting, low bioavailability, and systemic side effects. Nanozymes, which engineered nanomaterials with intrinsic enzyme-mimetic catalytic activities have recently emerged as a transformative therapeutic strategy capable of simultaneously modulating oxidative stress, inflammation, and lipid metabolism. This review comprehensively summarizes recent advances in nanozyme-based interventions for AS, focusing on representative systems such as Prussian blue, cerium oxide, selenium-based, and multifunctional composite nanozymes. We critically discuss their design principles, catalytic mechanisms, lesion-targeting strategies, and therapeutic outcomes in preclinical models. Additionally, we highlight key translational challenges, including biosafety concerns, pharmacokinetic limitations, and manufacturing standardization, which currently impede clinical application. By integrating catalytic activity with targeted delivery and microenvironment-responsive functionalities, nanozymes offer a promising paradigm for precision therapy in AS. Future research should prioritize enhancing biocompatibility, optimizing therapeutic specificity, and establishing scalable, reproducible fabrication ...